KR20200088824A - 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물 - Google Patents

근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물 Download PDF

Info

Publication number
KR20200088824A
KR20200088824A KR1020207015250A KR20207015250A KR20200088824A KR 20200088824 A KR20200088824 A KR 20200088824A KR 1020207015250 A KR1020207015250 A KR 1020207015250A KR 20207015250 A KR20207015250 A KR 20207015250A KR 20200088824 A KR20200088824 A KR 20200088824A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
treatment
eye
ophthalmic
atropine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207015250A
Other languages
English (en)
Korean (ko)
Inventor
미나스 테오도르 코로네오
모니카 종
파드마자 라자고팔 산카리두르그
얼리 레오 스미스 3세
아만딥 카우르
Original Assignee
브리엔 홀덴 비전 인스티튜트 리미티드
미나스 테오도르 코로네오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리엔 홀덴 비전 인스티튜트 리미티드, 미나스 테오도르 코로네오 filed Critical 브리엔 홀덴 비전 인스티튜트 리미티드
Publication of KR20200088824A publication Critical patent/KR20200088824A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207015250A 2017-11-03 2018-11-02 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물 Ceased KR20200088824A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
US62/581,112 2017-11-03
PCT/AU2018/051187 WO2019084621A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Publications (1)

Publication Number Publication Date
KR20200088824A true KR20200088824A (ko) 2020-07-23

Family

ID=66331107

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015250A Ceased KR20200088824A (ko) 2017-11-03 2018-11-02 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물

Country Status (10)

Country Link
US (1) US20200345633A1 (https=)
EP (1) EP3703691A4 (https=)
JP (2) JP2021501803A (https=)
KR (1) KR20200088824A (https=)
CN (3) CN111787920A (https=)
AU (1) AU2018359013A1 (https=)
CA (1) CA3081593A1 (https=)
SG (1) SG11202004005RA (https=)
TW (1) TW201932104A (https=)
WO (1) WO2019084621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (de) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Bestimmung einer veränderung eines refraktionsfehlers eines auges
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
US20240261291A1 (en) * 2021-06-11 2024-08-08 Brien Holden Vision Institute Limited Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
CN119139472A (zh) * 2024-09-26 2024-12-17 温州医科大学附属眼视光医院 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
WO1995033451A1 (en) * 1994-06-06 1995-12-14 Warner-Lambert Company Non-sedating allergy sinus medication
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU5312198A (en) * 1997-01-06 1998-08-03 Klaus Trier Aps Screening method
LT2493474T (lt) * 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Also Published As

Publication number Publication date
AU2018359013A1 (en) 2020-05-21
CN118384160A (zh) 2024-07-26
JP2023179418A (ja) 2023-12-19
SG11202004005RA (en) 2020-05-28
WO2019084621A1 (en) 2019-05-09
CN111787920A (zh) 2020-10-16
US20200345633A1 (en) 2020-11-05
EP3703691A1 (en) 2020-09-09
JP2021501803A (ja) 2021-01-21
EP3703691A4 (en) 2021-07-28
TW201932104A (zh) 2019-08-16
CA3081593A1 (en) 2019-05-09
CN118403054A (zh) 2024-07-30

Similar Documents

Publication Publication Date Title
US20250049761A1 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
KR20200088824A (ko) 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
JP7795555B2 (ja) 近視を治療するための方法及び薬物組成物
TW202337462A (zh) 採用長春西汀治療近視的方法
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
Galeana Prospective Interventional Non-Comparative Non-Randomized Clinical Study of A Topical Synergic Compound to Mitigate Presbyopia Effects
HK40011588A (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK40086794B (zh) 一种采用长春西汀治疗近视的方法
HK40086794A (zh) 一种采用长春西汀治疗近视的方法
HK1198426B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211101

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240315

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D